

INITIATION OF COVERAGE
Dave Storms, CFA
Dave@stonegateinc.com

214-987-4121

Market Statistics in CAD

Price	\$ 0.07
52 week Range	\$0.02 - \$0.12
Daily Vol (3-mo. average)	87,370
Market Cap (M)	\$ 18.1
Enterprise Value (M)	\$ 21.4
Shares Outstanding: (M)	258.8
Float (M)	248.9
Public Ownership	95.5%
Institutional Ownership	0.0%

Financial Summary in CAD

Cash (M)	\$ 0.0
Cash/Share	\$ 0.00
Debt (M)	\$ 3.3
Equity (M)	\$ (3.5)
Equity/Share	\$ (0.01)


COMPANY DESCRIPTION

Sirona Biochem Corp. is a Vancouver-based biotechnology company specializing in the stabilization and enhancement of carbohydrate-based molecules through proprietary fluorination chemistry, developed by its French subsidiary, TFChem. This innovation significantly improves the efficacy and safety of molecules, particularly in cosmetics and therapeutics. The Company's platform has fueled the development of groundbreaking skincare innovations and therapeutic ingredients. Sirona operates on a licensing model, partnering with large organizations to commercialize its patented compounds, generating revenue through upfront payments, milestone payments, and royalties.

SIRONA BIOCHEM CORP. (TSX-V: SBM OTC: SRBCF)
Company Overview

GlycoProteMim™: Premier Anti-Wrinkle Solution: GlycoProteMim™ is Sirona's most advanced product, a carbohydrate-based molecule targeting both surface and cellular-level skin aging processes. Clinical trials demonstrated significant results:

- 37% increase in skin density
- 54% reduction in oxidative stress and inflammation
- 75% of participants reported a visible reduction in wrinkles
- 25% increase in skin radiance
- 90% of participants noted improved quality of the skin.

These results make GlycoProteMim™ a standout in the premium skincare market. Sirona is positioning it as a top-tier anti-aging ingredient, engaging in strategic commercialization discussions with global partners across North America, South America, Europe, and Asia.

Key Licensing Agreement: In June 2022, Sirona entered into a global licensing agreement with Allergan Aesthetics (an AbbVie company) for its dark spot removing compound, TFC-1067. This agreement has accelerated Sirona's entry into the skincare space, providing a blueprint for future product launches, including GlycoProteMim™.

Financial Overview

Cash Position: As of July 31, 2024, Sirona had a cash balance of \$32,875, down from \$308,847 a year prior. The Company faces a working capital deficit of \$1.57 million and is actively pursuing both dilutive and non-dilutive financing options to support the commercialization of GlycoProteM™ and other products. Although funding is a challenge, management is confident that its commercialization efforts will drive shareholder value, potentially leading to profitability by 2025.

Revenue and Profitability

- Fiscal 2023 revenue: \$34,779 (down from \$671,923 in 2022)
- Net loss for fiscal 2023: \$2.5 million Sirona aims to achieve profitability in 2025 with a successful launch of GlycoProteM™, which could trigger substantial revenue in key global markets.

Key Financial Metrics (as of July 31, 2024)

- **Total assets:** \$1.0 million
- **Total liabilities:** \$3.5 million
- **Shareholders' equity:** \$2.5 million (up from a deficit of \$214,515 in October 2023).

Business Overview

Sirona Biochem Corp. is a Vancouver-based biotechnology company specializing in the stabilization and enhancement of carbohydrate-based molecules through proprietary carbohydrate chemistry, developed by its French subsidiary, TFChem. This innovation significantly improves the efficacy and safety of molecules, particularly in cosmetics and therapeutics. The Company's platform has fueled the development of groundbreaking skincare innovations and therapeutic ingredients. Sirona operates on a licensing model, partnering with large organizations to commercialize its patented compounds, generating revenue through upfront payments, milestone payments, and royalties. Additionally, Sirona is planning its own commercial launch in select markets.

Key programs include:

- **TFC-1067:** Licensed to Allergan Aesthetics for dyschromia treatments.
- **GlycoProteM™:** Sirona's flagship anti-aging compound poised to enter the global skincare market.

Strategic Pipeline and Global Reach

Beyond GlycoProteMim™, Sirona's pipeline is rich with potential. The Company continues to innovate, focusing on cosmetic and therapeutic ingredients. Current development areas include anti-aging, anti-cellulite, and wound care compounds, with key markets targeted across Japan, China, Europe, and North America. Sirona's French research team is at the forefront, working on next-generation carbohydrate-based molecules.

Investment Outlook

Key Investment Drivers

- **GlycoProteMim™ Positioned for Success:** With strong clinical results showcasing improvements in skin health, GlycoProteMim™ has the potential to disrupt the premium anti-aging market. Sirona's active pursuit of partnerships in key regions enhances its global market potential.
- **Path to Profitability:** Sirona is targeting profitability by 2025, with expected revenue from Allergan Aesthetic and the commercialization of GlycoProteMim™ set to drive growth.
- **Global Expansion Strategy:** Sirona's partnerships in Japan, Europe, North and South America, as well as emerging markets like China and India place it in a strong position to capture significant market share in the growing global skincare industry.
- **Innovative Product Pipeline:** Sirona's cutting-edge research continues to produce promising new molecules, providing further opportunities for growth and innovation.

Risks

- **Funding Needs:** Sirona's ability to secure sufficient funding is critical for its upcoming product launches and continued R&D efforts.
- **Commercialization Timeline:** Delays in regulatory approvals, manufacturing, or distribution could impact Sirona's financial projections.
- **Highly Competitive Market:** The skincare market is saturated with established players. Sirona's success depends on its ability to differentiate and capture market share

Income Statement			
For the Fiscal Period Ending	Oct-31-2022	Oct-31-2023	Jul-31-2024
Currency	CAD	CAD	CAD
Revenue	0.672	0.035	(0.016)
Other Revenue	-	-	-
Total Revenue	0.672	0.035	(0.016)
Cost Of Goods Sold	0.05	0.064	0.065
Gross Profit	0.622	(0.029)	(0.081)
Selling General & Admin Exp.	1.645	1.252	1.084
Stock-Based Compensation	1.465	0.031	0.188
R & D Exp.	0.892	0.991	0.902
Depreciation & Amort.	0.009	0.01	0.01
Other Operating Expense/(Income)	-	-	-
Other Operating Exp., Total	4.011	2.284	2.184
Operating Income	(3.39)	(2.313)	(2.266)
Interest Expense	(0.027)	(0.202)	(0.405)
Interest and Invest. Income	-	-	-
Net Interest Exp.	(0.027)	(0.202)	(0.405)
Currency Exchange Gains (Loss)	0.006	(0.003)	(0.001)
Other Non-Operating Inc. (Exp.)	(0.142)	(0.027)	0.008
EBT Excl. Unusual Items	(3.552)	(2.544)	(2.663)
Impairment of Goodwill	-	-	-
Other Unusual Items	-	-	-
EBT Incl. Unusual Items	(3.552)	(2.544)	(2.663)
Income Tax Expense	0.006	(0.001)	0.003
Earnings from Cont. Ops.	(3.558)	(2.543)	(2.666)
Earnings of Discontinued Ops.	-	-	-
Extraord. Item & Account. Change	-	-	-
Net Income to Company	(3.558)	(2.543)	(2.666)
Minority Int. in Earnings	-	-	-
Net Income	(3.558)	(2.543)	(2.666)
Pref. Dividends and Other Adj.	-	-	-
NI to Common Incl Extra Items	(3.558)	(2.543)	(2.666)
NI to Common Excl. Extra Items	(3.558)	(2.543)	(2.666)
Per Share Items			
Basic EPS	(0.01)	(0.01)	(0.01)
Basic EPS Excl. Extra Items	(0.01)	(0.01)	(0.01)
Weighted Avg. Basic Shares Out.	241.039	252.101	254.929

Balance Sheet				
Balance Sheet as of:	Oct-31-2022	Oct-31-2023	Oct-31-2023	Jul-31-2024
Currency	CAD	CAD	CAD	CAD
ASSETS				
Cash And Equivalents	0.422	0.571	0.571	0.033
Short Term Investments	0.001	0.001	0.001	0.001
Total Cash & ST Investments	0.422	0.572	0.572	0.034
Accounts Receivable	0.024	0.007	0.007	0.005
Other Receivables	0.773	0.438	0.438	0.762
Total Receivables	0.797	0.444	0.444	0.768
Prepaid Exp.	0.053	0.006	0.006	0.006
Other Current Assets	-	-	-	-
Total Current Assets	1.272	1.023	1.023	0.808
Net Property, Plant & Equipment	0.019	0.009	0.009	0.002
Other Long-Term Assets	-	-	-	-
Total Assets	1.291	1.032	1.032	0.809
LIABILITIES				
Accounts Payable	0.316	1.117	1.117	0.808
Short-term Borrowings	-	0.454	0.454	1.523
Curr. Port. of LT Debt	0.338	0.184	0.184	0.018
Curr. Port. of Leases	0.036	0.006	0.006	-
Other Current Liabilities	0.175	0.106	0.106	0.028
Total Current Liabilities	0.865	1.867	1.867	2.377
Long-Term Debt	0.091	1.539	1.539	1.778
Long-Term Leases	0.005	-	-	-
Pension & Other Post-Retire. Benefits	0.115	0.137	0.137	0.118
Other Non-Current Liabilities	-	-	-	-
Total Liabilities	1.076	3.543	3.543	4.273
Common Stock	34.487	34.661	34.661	35.134
Additional Paid In Capital	7.309	7.329	7.329	7.477
Retained Earnings	(41.358)	(43.901)	(43.901)	(45.936)
Treasury Stock	-	-	-	-
Comprehensive Inc. and Other	(0.224)	(0.601)	(0.601)	(0.139)
Total Common Equity	0.215	(2.511)	(2.511)	(3.464)
Total Equity	0.215	(2.511)	(2.511)	(3.464)
Total Liabilities And Equity	1.291	1.032	1.032	0.809

Executive Overview



Howard J. Verrico, MD
CEO and Chairman of the Board

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a venture capitalist for over 30 years, funding numerous start-ups and early-stage companies both in the private and public marketplace. He is the original founder of Sirona Biochem building the company by investing his personal funds starting in 2006. He has accumulated his large share position through personal share purchases. He currently is solely focused on the success and growth of SIRONA Biochem as it enters a stage of rapid growth.



Géraldine Deliencourt-Godefroy, PhD
Chief Scientific Officer

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology for stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Master's in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.



Christopher Hopton, CPA
Chief Financial Officer

Christopher Hopton brings 28 years of financial management and operations expertise to the company. His extensive background includes financial planning, accounting policy, and business process improvement. As a business investment and finance consultant, he has worked with various public and private companies. Noteworthy roles include serving as Chief Financial Officer at Central Resources Corp. and Rio Silver Inc., as well as Division Controller at Canadian Airlines, where he managed a \$200 million annual operating budget. He played a key role in the restructuring of 360 Networks, leading to its acquisition by Bell Canada. Mr. Hopton holds a Bachelor of Business Administration from Simon Fraser University and is a Certified Professional Accountant.

IMPORTANT DISCLOSURES AND DISCLAIMER

- (a) The research analyst and/or a member of the analyst's household do not have a financial interest in the debt or equity securities of the subject company.
- (b) The research analyst responsible for the preparation of this report has not received compensation that is based upon Stonegate's investment banking revenues.
- (c) Stonegate or any affiliate have not managed or co-managed a public offering of securities for the subject company in the last twelve months, received investment banking compensation from the subject company in the last 12 months, nor expects or receive or intends or seek compensation for investment banking services from the subject company in the next three months.
- (d) Stonegate's equity affiliate, Stonegate Capital Partners, "SCP" has a contractual agreement with the subject company to provide research services, investor relations support, and investor outreach. SCP receives a monthly retainer for these non-investment banking services.
- (e) Stonegate or its affiliates do not beneficially own 1% or more of any class of common equity securities of the subject company.
- (f) Stonegate does not make a market in the subject company.
- (g) The research analyst has not received any compensation from the subject company in the previous 12 months.
- (h) Stonegate, the research analyst, or associated person of Stonegate with the ability to influence the content of the research report knows or has reason to know of any material conflicts of interest at the time of publication or distribution of the research report.
- (i) No employee of Stonegate has a position as an officer or director of the subject company.

Ratings - Stonegate does not provide ratings for the companies covered.

Distribution of Ratings - Stonegate does not provide ratings for covered companies.

Price Chart - Stonegate does not have, nor has previously had, a rating for its covered companies.

Price Targets - Stonegate does not provide price targets for its covered companies. However, Stonegate does provide valuation analysis.

Regulation Analyst Certification:

I, Dave Storms, CFA, hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report.

For Additional Information Contact:

Stonegate Capital Markets, Inc.

Dave Storms, CFA

Dave@stonegateinc.com

214-987-4121

Please note that this report was originally prepared and issued by Stonegate for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of Stonegate should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. The information contained herein is based on sources which we believe to be reliable but is not necessarily complete and its accuracy cannot be guaranteed. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of Stonegate Capital Markets and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein. The firm and/or its employees and/or its individual shareholders and/or members of their families and/or its managed funds may have positions or warrants in the securities mentioned and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the firm from time to time in the open market or otherwise. While we endeavor to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. All opinions are subject to change without notice, and we do not undertake to advise you of any such changes. Reproduction or redistribution of this report without the expressed written consent of Stonegate Capital Markets is prohibited. Additional information on any securities mentioned is available on request.